A PHASE IB DOSE-ESCALATION TRIAL OF ISATUXIMAB (SAR650984, ANTI-CD38 MAB) PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM RESULTS FROM 2 NEW DOSE COHORTS

被引：0
|
作者：
Lendvai, N. [1 ]
Vij, R.
Martin, T. G. [2 ]
Baz, R. [3 ]
Campana, F. [4 ]
Mazuir, F. [5 ]
Charpentier, E. [4 ]
Benson, D. M. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Sanofi Oncol, Cambridge, MA USA
[5] Sanofi Res & Dev, Alfortville, France
[6] Ohio State Univ, Columbus, OH 43210 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P278
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [1] A phase lb dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.
    Vij, Ravi
    Lendvai, Nikoletta
    Martin, Thomas G.
    Baz, Rachid C.
    Campana, Frank
    Mazuir, Florent
    Charpentier, Eric
    Benson, Don M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Martin, Thomas G.
    Baz, Rachid
    Benson, Don M.
    Lendvai, Nikoletta
    Campana, Frank
    Charpentier, Eric
    Vij, Ravi
    BLOOD, 2014, 124 (21)
  • [3] A PHASE IB DOSE ESCALATION TRIAL OF SAR650984 (ANTI-CD-38 MAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Martin, T.
    Baz, R.
    Benson, D.
    Lendvai, N.
    Vij, R.
    Charpentier, E.
    Hsu, K.
    HAEMATOLOGICA, 2014, 99 : 114 - 114
  • [4] Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
    Richter, Joshua Ryan
    Martin, Thomas G.
    Vij, Ravi
    Cole, Craig
    Atanackovic, Djordje
    Zonder, Jeffrey A.
    Kaufman, Jonathan L.
    Mikhael, Joseph
    Bensinger, William
    Dimopoulos, Meletios A.
    Zimmerman, Todd M.
    Lendvai, Nikoletta
    Hari, Parameswaran
    Ocio, Enrique M.
    Gasparetto, Cristina
    Kumar, Shaji
    Oprea, Corina
    Charpentier, Eric
    Strickland, Stephen Anthony
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma
    Martin, Thomas
    Richter, Joshua
    Vij, Ravi
    Cole, Craig
    Atanackovic, Djordje
    Zonder, Jeffrey
    Kaufman, Jonathan L.
    Bensinger, William
    Dimopoulos, Meletios A.
    San Miguel, Jesus
    Zimmerman, Todd
    Lendvai, Nikoletta
    Hari, Parameswaran
    Ocio, Enrique M.
    Gasparetto, Cristina
    Kumar, Shaji
    Hsu, Karl
    Charpentier, Eric
    Strickland, Stephen A.
    Mikhael, Joseph
    BLOOD, 2015, 126 (23)
  • [6] UPDATED DATA FROM A PHASE II DOSE FINDING TRIAL OF SINGLE AGENT ISATUXIMAB (SAR650984, ANTI-CD38 MAB) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Vij, R.
    Martin, T.
    Richter, J.
    Cole, C.
    Atanackovic, D.
    Zonder, J.
    Kaufman, J.
    Mikhael, J.
    Bensinger, W.
    Dimopoulos, M.
    Zimmerman, T.
    Lendvai, N.
    Hari, P.
    Ocio, E. M.
    Gasparetto, C.
    Kumar, S.
    Oprea, C.
    Charpentier, E.
    Strickland, S.
    San Miguel, J.
    HAEMATOLOGICA, 2016, 101 : 82 - 83
  • [7] A phase lb dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.
    Martin, Thomas G.
    Hsu, Karl
    Charpentier, Eric
    Vij, Ravi
    Baz, Rachid C.
    Benson, Don M.
    Lendvai, Nikoletta
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richter, Joshua
    Vij, Ravi
    Cole, Craig
    Zonder, Jeffrey
    Kaufman, Jonathan L.
    Bensinger, William
    Dimopoulos, Meletios
    Lendvai, Nikoletta
    Hari, Parameswaran
    Ocio, Enrique M.
    Gasparetto, Cristina
    Kumar, Shaji
    Oprea, Corina
    Chiron, Marielle
    Brillac, Claire
    Charpentier, Eric
    San-Miguel, Jesus
    Martin, Thomas
    LEUKEMIA, 2020, 34 (12) : 3298 - 3309
  • [9] A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
    Joseph Mikhael
    Joshua Richter
    Ravi Vij
    Craig Cole
    Jeffrey Zonder
    Jonathan L. Kaufman
    William Bensinger
    Meletios Dimopoulos
    Nikoletta Lendvai
    Parameswaran Hari
    Enrique M. Ocio
    Cristina Gasparetto
    Shaji Kumar
    Corina Oprea
    Marielle Chiron
    Claire Brillac
    Eric Charpentier
    Jesús San-Miguel
    Thomas Martin
    Leukemia, 2020, 34 : 3298 - 3309
  • [10] Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Weller, Edie
    Jagannath, Sundar
    Avigan, David E.
    Alsina, Melissa
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    McKenney, Mary
    Delaney, Carol
    Mitsiades, Constantine S.
    Hideshima, Teru
    Dalton, William
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5713 - 5719
12345